All news

Superbugs under the microscope as international experts gather at Queen’s

6/09/2016


Scientists from across Europe who are leading the fight against superbugs will gather at Queen’s University Belfast next week (14-15 September 2016).

They will join researchers from Queen’s who are pioneering a new approach in the ‘arms race’ against antibiotic resistant infections.

Queen’s scientists are working towards the development of new therapies to boost the body’s own defenses against infection, rather than trying to beat the bugs by attacking them directly with antibiotics.

The approach is called ‘host directed therapeutics’ and it focusses on identifying the ‘achilles heel’ within the immune system that allows infection-causing microbes to take hold.

It is one of the approaches that will be discussed during the two-day event, hosted by Professor Jose Bengoechea, Director of Centre for Experimental Medicine at Queen’s.

Professor Bengoechea’s research into combatting the multidrug-resistant microbe Klebsiella Pneumoniae is recognised worldwide.

The conference marks the end of the four-year INBIONET programme (Infection Biology Training Network), which is led by Queen’s and funded by the Marie Curie Initial Training Network Scheme as part of the EU’s Seventh Framework Programme.

For further information on the conference click here.

Media inquiries to Anne-Marie Clarke (Mon-Wed) or Michelle Cassidy (Thu-Fri) at Queen’s Communications Office, T: +44 (0)28 9097 5310 E: comms.officer@qub.ac.uk

More news and features

Renewable energy

€9.7 million renewable energy centre opens at Queen’s University Belfast

17/01/2018 - A €9.7 million cross-border research centre for renewable energy projects has been opened at Queen’s University Belfast.

Science

Queen's scientist will test the limits of quantum theory

16/01/2018 - A scientist from Queen's University is working with researchers at two other UK universities to test one of the fundamental laws of physics as part of a major Europe-wide project awarded more than £3m in funding.